Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29040621.
- Also identified by DOI 10.1093/infdis/jix413 and PMC identifier 5853236.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Healthcare delivery has advanced due to the implementation of point-of-care testing, which is often performed within minutes to hours in minimally equipped laboratories or at home. Technologic advances are leading to point-of-care kits that incorporate nucleic acid-based assays, including polymerase chain reaction, isothermal amplification, ligation, and hybridization reactions. As a limited number of single-nucleotide polymorphisms are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to detect these mutations have been developed. Early versions of these assays have been used in research. This review summarizes the principles underlying each assay and discusses strategic needs for their incorporation into the management of HIV infection.
Medical subject headings
- Anti-HIV Agents
- HIV
- HIV Infections
- Point-of-Care Testing